Impax Ends Acne Drug Pay-For-Delay Suit For $20M

By Chris Villani (March 29, 2018, 11:39 AM EDT) -- Impax Laboratories Inc. on Thursday reached a $20 million midtrial settlement with a class of consumers and insurers, ending a suit in Massachusetts federal court that claimed the lab delayed the launch of a generic acne medicine in exchange for a $40 million payment.

The settlement was revealed in court papers Thursday morning, and is the last in a long line of settlements resolving the litigation, which was first consolidated in Massachusetts in 2014. The suit claimed Impax waited three years to launch its generic version of Solodyn after reaching an agreement in 2008 with Medicis Pharmaceutical Corp, the maker of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!